ES2105257T3 - Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor. - Google Patents

Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor.

Info

Publication number
ES2105257T3
ES2105257T3 ES93909917T ES93909917T ES2105257T3 ES 2105257 T3 ES2105257 T3 ES 2105257T3 ES 93909917 T ES93909917 T ES 93909917T ES 93909917 T ES93909917 T ES 93909917T ES 2105257 T3 ES2105257 T3 ES 2105257T3
Authority
ES
Spain
Prior art keywords
stabilized
pharmaceutical compositions
compositions containing
reducing sugar
sucrosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909917T
Other languages
English (en)
Inventor
Fabrizio Samaritani
Filippo Rendina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2105257T3 publication Critical patent/ES2105257T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS BASADOS EN INTERLEUQUINA-6 (IL-6) ESTABILIZADA CON AZUCARES NO REDUCTORES, TALES COMO SUCROSA Y TREHALOSA. LAS COMPOSICIONES TAMBIEN PUEDEN CONTENER UN AMINOACIDO O ALBUMINA HUMANA COMO EXCIPIENTE. LA FORMULACION ES PARTICULARMENTE APROPIADA PARA LA ESTABILIZACION DE POLVO SECO Y CONGELADO DE IL-6 RECOMBINANTE.
ES93909917T 1992-05-11 1993-05-07 Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor. Expired - Lifetime ES2105257T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM920349A IT1254359B (it) 1992-05-11 1992-05-11 Composizioni farmaceutiche contenenti il-6

Publications (1)

Publication Number Publication Date
ES2105257T3 true ES2105257T3 (es) 1997-10-16

Family

ID=11400994

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93909917T Expired - Lifetime ES2105257T3 (es) 1992-05-11 1993-05-07 Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor.

Country Status (12)

Country Link
US (1) US5635176A (es)
EP (1) EP0641216B1 (es)
JP (1) JP3714951B2 (es)
AT (1) ATE157256T1 (es)
AU (1) AU676833B2 (es)
CA (1) CA2117761C (es)
DE (1) DE69313444T2 (es)
DK (1) DK0641216T3 (es)
ES (1) ES2105257T3 (es)
GR (1) GR3024708T3 (es)
IT (1) IT1254359B (es)
WO (1) WO1993023065A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
EP0748213B1 (en) 1994-03-07 2004-04-14 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
WO1996024369A1 (en) * 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19539574A1 (de) 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433760B1 (en) 1999-01-14 2002-08-13 University Of Central Florida Head mounted display with eyetracking capability
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2002053136A1 (en) * 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
WO1987000196A1 (en) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
EP0645452A1 (en) * 1985-10-14 1995-03-29 Yeda Research And Development Co. Ltd. Human interferon-beta 2A and interfeon-beta 2B, vectors containing genes coding for said interferons, cell lines producing same and use of said interferons as pharmaceuticals
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP2805224B2 (ja) * 1989-01-13 1998-09-30 味の素株式会社 血小板減少症治療剤
JPH0327320A (ja) * 1989-06-26 1991-02-05 Ajinomoto Co Inc ヒトｂ細胞分化因子医薬組成物
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
WO1993006840A1 (en) * 1991-10-09 1993-04-15 Toray Industries, Inc. Medicine for preventing and treating bleeding tendency
JP3027320U (ja) 1996-01-27 1996-08-09 三千男 高橋 野球グラブの装着補強具

Also Published As

Publication number Publication date
IT1254359B (it) 1995-09-14
WO1993023065A1 (en) 1993-11-25
AU676833B2 (en) 1997-03-27
AU4065393A (en) 1993-12-13
EP0641216A1 (en) 1995-03-08
DE69313444D1 (de) 1997-10-02
EP0641216B1 (en) 1997-08-27
JPH08502722A (ja) 1996-03-26
DK0641216T3 (da) 1998-01-26
CA2117761C (en) 2005-10-04
ITRM920349A1 (it) 1993-11-11
ATE157256T1 (de) 1997-09-15
US5635176A (en) 1997-06-03
CA2117761A1 (en) 1993-11-25
ITRM920349A0 (it) 1992-05-11
JP3714951B2 (ja) 2005-11-09
DE69313444T2 (de) 1998-01-02
GR3024708T3 (en) 1997-12-31

Similar Documents

Publication Publication Date Title
ES2105257T3 (es) Composiciones farmaceuticas que contienen il-6 estabilizadas con un azucar no reductor.
ES2117781T3 (es) Preparaciones farmaceuticas liofilizadas y estables de g-csf.
PT74703B (en) Process for the preparation of pharmaceutical compositions for topical use which are penetrable through the skin and contain as an active ingredient amongst others (e)-n-methyl-6,6-dimethyl-n-(naphtylmethyl)-hept-2-en-4-inyl-1-amine
DK569982A (da) Fysiologisk aktive peptider samt fremgangsmaade til fremstilling af transformanter, der producerer saadanne peptider
ES8506089A1 (es) Un procedimiento para preparar una celula u organismo recombinante
NO905472D0 (no) Insulinanaloger fra menneske og blandinger som inneholderdem.
ES2051678T1 (es) Derivados de 5-oxo-l-prolina y uso farmaceutico de los mismos.
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
PT94326A (pt) Processo para a preparacao de polipeptidios e seus analogos e de composicoes farmaceuticas que os contem
DE58905681D1 (de) Pharmazeutische Präparate zur verbesserten Resorption antibakterieller Verbindungen.
IL87778A0 (en) Pharmaceutical compositions containing stabilized therapeutically active proteins and their preparation
GB2021409A (en) Pharmaceutical composition
MX9207199A (es) Composicion farmaceutica estabilizada de il2 recombinante humana no glicosilada en forma reducida, que comprende acido citrico, manitol y procedimien to para su preparacion.
ITMI911059A0 (it) Acido metiltauroursodesossicolico e suoi derivati terapeuticamente attivi procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono
AU6278680A (en) Carbamates and pharmaceutical formulations containing them
IT8222911A0 (it) Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
ES2054029T3 (es) Formulacion de acetato de flecainida con liberacion controlada.
ES2018656B3 (es) Nuevos derivados del acido 16,17-acetal sustituido, procedimiento de preparacion del mismo y preparaciones farmaceuticas que los contienen.
IT8021037A0 (it) Composizioni insetticide che esteri sostituiti dell'acido contengono i medesimi come ciclopropancarbossilico e ingrediente attivo.
IT8148807A0 (it) Esteri della 2-tenoilmercaptopropio nil glicina con idrossibenzeni sostituiti procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
IT1147733B (it) Procedimento per la preparazione di esaidro pirimido (1,2-a) azepine 3-sostitlite,composizioni farmaceutiche che le contengono e esaidro pirimido (1,2-a) azepine 3-sostituite
SE7601928L (sv) Pyrimidin(2)yl-tionofosforsyraestrar till anvendning som insekticider och akaricider samt sett att framstella desamma
ES291524U (es) Recipiente termoaislante
MX9101804A (es) Composicion para preparaciones farmaceuticas solidas con vitaminas de activas y procedimiento para la preparacion de las mismas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641216

Country of ref document: ES